TNFSF11 and neoplasm: Targeting RANKL seems to be a promising anti-tumor approach, but unfortunately, the randomized open-label phase III SPLENDOUR trial, which was designed to evaluate whether the addition of denosumab to standard first-line platinum-based doublet chemotherapy improved OS in advanced NSCLC, failed to demonstrate a clinical benefit (21).